Literature DB >> 9729419

Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7).

D F Emerich1, P Snodgrass, M Pink, F Bloom, R T Bartus.   

Abstract

The bradykinin analog, Cereport (RMP-7), was designed to increase permeability of the blood brain barrier (BBB). Over the past several years it has been developed primarily as a means of increasing permeability of the blood brain tumor barrier, where early evidence indicated a particularly robust and reliable effect. The present series of experiments were intended to determine whether Cereport might also be used to increase delivery of pharmacological agents across the normal (i.e., non-tumor) BBB. This was accomplished by testing the ability of Cereport to enhance delivery of the peripherally acting opiate agonist, loperamide, to the brain, as evidenced by induction of a centrally mediated analgesic effect. Intravenous administration of a combination of Cereport and loperamide produced a significant analgesic effect (2-fold increase in response times) when animals were tested on a hotplate apparatus. Loperamide alone did not produce analgesia. An analysis of the time course of analgesia revealed a graded onset of analgesia which peaked at 30 min, maintained asymptote at 60 min, and began to diminish by 120 min following Cereport and loperamide administration. Finally, the analgesic effects of combining Cereport and loperamide were completely blocked when animals were pre-treated with the opiate antagonist naloxone, demonstrating that the analgesia was mediated through opiate receptors. Collectively, these results suggest that Cereport was able to increase delivery of loperamide across the BBB, allowing it to gain access to opiate receptors in the CNS to produce a centrally mediated analgesic effect. They therefore provide clear evidence that safe and well-tolerated doses of Cereport can increase permeability of the normal (i.e., non-tumor) BBB. Moreover, they provide the first evidence of a pharmacological effect specifically enabled by controlled (i.e., receptor-mediated) modulation of the BBB. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9729419     DOI: 10.1016/s0006-8993(98)00571-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

Review 1.  Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Authors:  Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

2.  Loperamide dependence and abuse.

Authors:  Ryan MacDonald; Jason Heiner; Joshua Villarreal; Jared Strote
Journal:  BMJ Case Rep       Date:  2015-05-02

3.  Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors.

Authors:  Yot Navalitloha; Erica S Schwartz; Elizabeth N Groothuis; Cathleen V Allen; Robert M Levy; Dennis R Groothuis
Journal:  Neuro Oncol       Date:  2006-06-14       Impact factor: 12.300

4.  Intravenous infusion of cereport increases uptake and efficacy of acyclovir in herpes simplex virus-infected rat brains.

Authors:  D J Bidanset; L Placidi; R Rybak; J Palmer; J P Sommadossi; E R Kern
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 5.  The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation.

Authors:  D F Emerich; R L Dean; C Osborn; R T Bartus
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 6.  Stroke, dementia, and drug delivery.

Authors:  G A Ford; C A Bryant; A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

7.  Influence of short-chain cell-penetrating peptides on transport of doxorubicin encapsulating receptor-targeted liposomes across brain endothelial barrier.

Authors:  Gitanjali Sharma; Amit Modgil; Tiecheng Zhong; Chengwen Sun; Jagdish Singh
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

8.  Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone.

Authors:  Stephen R Morairty; Florent G Revel; Pari Malherbe; Jean-Luc Moreau; Daniel Valladao; Joseph G Wettstein; Thomas S Kilduff; Edilio Borroni
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

9.  A Novel Maintenance Therapeutic for Opioid Use Disorder.

Authors:  Beth Youngblood; Kevin Li; Donald R Gehlert; Julio C Medina; Neil Schwartz
Journal:  J Pharmacol Exp Ther       Date:  2021-05-19       Impact factor: 4.402

Review 10.  Drug interactions at the blood-brain barrier: fact or fantasy?

Authors:  Sara Eyal; Peng Hsiao; Jashvant D Unadkat
Journal:  Pharmacol Ther       Date:  2009-04-22       Impact factor: 13.400

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.